However, Concert, and upon acquisition, Sun Pharma will be facing stiff competition from prominent players in the medical market like Pfizer ( PFE - Free Report ) and Eli Lilly and Company ( LLY - Free Report ). In September 2022, Pfizer announced that the FDA had accepted its NDA filing for its candidate, ritlecitinib, a selective JAK3/TEC kinase inhibitor, for adults and adolescents 12 years of age and older with alopecia areata.